We are delighted to announce that a poster on Tumor-reactive γδ T Cells Mediate Responses to the Antibody Drug Conjugate Belantamab Mafodotin in Multiple Myeloma was presented at the International Myeloma Society (IMS) meeting and subsequently published in Clinical Lymphoma Myeloma & Leukemia in September 2025.

Congratulations to Liam Hendrikse and the participating CMRG investigators for this outstanding publication and scientific contribution.

We also extend our deepest gratitude to the patients who generously participated in the Algonquin-CMRG-007 study and provided samples, without which this work would not be possible.

Read the article here.